

INNATE IMMUNITY

Sensing viruses



Recently there have been marked advances in determining the mechanisms by which innate immune cells respond to intracellular pathogens. The use of *in vitro* studies has resulted in the identification of mitochondrial antiviral signalling protein (MAVS; also known as IPS1, CARDIF and

VISA) as an important adaptor protein that can link intracellular pathogen recognition with activation of the transcription factors nuclear factor- κ B (NF- κ B) and interferon-regulatory factor 3 (IRF3). New research shows a specific and essential role for MAVS *in vivo* in the innate immune response to viruses.

To elucidate the role of MAVS *in vivo*, Sun *et al.* generated *Mavs*^{-/-} mice by homologous recombination. *Mavs*^{-/-} and *Mavs*^{+/-} mice infected with vesicular stomatitis virus (VSV) (an RNA virus) died within 4 days of infection, whereas most wild-type mice survived. This indicates an important role for MAVS in protection against VSV-induced mortality. In addition, mouse embryonic fibroblasts (MEFs) from *Mavs*^{-/-} mice were more permissive to VSV replication compared with MEFs from wild-type mice.

Infection of MEFs, macrophages and conventional dendritic cells from *Mavs*^{-/-} mice with Sendai virus (SEV) (an RNA virus) did not activate either NF- κ B or IRF3, or induce type I interferons (IFNs). However, induction of type I IFNs was intact in *Mavs*^{-/-} mice in response to Toll-like receptor (TLR) ligands, such as lipopolysaccharide and the synthetic double-stranded RNA analogue poly I:C (polyinosinic-polycytidylic acid). Because activation of NF- κ B and IRF3 by viruses involves at least two signalling pathways — the TLR-signalling pathway and a pathway that uses cytoplasmic receptors, such as retinoic-acid-inducible gene I (RIG-I) and melanoma-differentiation-associated gene 5 (MDA5) — these data indicate that MAVS is required

for antiviral immunity but not for TLR-induced immune responses.

Interestingly, induction of type I IFNs by transfection of MEFs with poly I:C, which introduces the RNA analogue into the cytosol, was dependent on MAVS. In addition, MAVS is required for type I IFN induction by poly I:C *in vivo*. A recent study has shown that IFN β production induced by SEV and VSV requires RIG-I, whereas transfected poly I:C induces IFN β production through MDA5. Therefore, it would seem that MAVS functions downstream of both of these receptors and might function as a convergence point for these signalling pathways.

Recent studies have also indicated that MAVS might be involved in the induction of type I IFNs in response to cytosolic B-form DNA and *Listeria monocytogenes*. However, induction of type I IFNs by macrophages transfected with B-form DNA or infected with *L. monocytogenes* was similar in *Mavs*^{-/-} mice and wild-type mice. Similarly, a recent study published in *FEBS Letters* also showed, using siRNA (small interfering RNA)-mediated knockdown of *Mavs*, that loss of MAVS did not affect induction of type I IFNs by *L. monocytogenes*.

Therefore, MAVS is not an adaptor protein for all cytoplasmic pathogen sensors, but does have a specific and essential role in antiviral immunity independent of TLR signalling.

Olive Leavy

ORIGINAL RESEARCH PAPERS Sun, Q. *et al.* The specific and essential role of MAVS in antiviral innate immune responses. *Immunity* **24**, 633–642 (2006) | Soulat, D. *et al.* Cytoplasmic *Listeria monocytogenes* stimulates IFN- β synthesis without requiring the adapter protein MAVS. *FEBS Lett.* **580**, 2341–2346 (2006)

RESEARCH HIGHLIGHTS ADVISORS

CEZMI AKDIS
Swiss Institute of Allergy and Asthma Research, Davos, Switzerland
BRUCE BEUTLER
The Scripps Research Institute, La Jolla, USA
PETER CRESSWELL
Yale University, New Haven, USA

JAMES DI SANTO
Institut Pasteur, Paris, France
GARY KORETZKY
University of Pennsylvania, Philadelphia, USA
CHARLES MACKAY
Garvan Institute of Medical Research, Sydney, Australia

CORNELIS MELIEF
Leiden University Medical Center, Leiden, The Netherlands
MICHEL NUSSENZWEIG
The Rockefeller University, New York, USA
RICHARD RANSOHOFF
The Cleveland Clinic Foundation, Cleveland, USA

ALAN SHER
National Institute of Allergy and Infectious Diseases, Bethesda, USA
ANDREAS STRASSER
The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

MEGAN SYKES
Harvard Medical School, Boston, USA
ERIC VIVIER
Centre d'Immunologie de Marseille-Luminy, Marseille, France
MATTHIAS VON HERRATH
La Jolla Institute for Allergy and Immunology, San Diego, USA